Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05064735 · ClinicalTrials.gov registry record · Phase 3
Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
A Phase 3 study of Obesity, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 407
- Enrollment target
- 20
- Study locations
NCT05064735: Completed Phase 3 study of Obesity, sponsored by Novo Nordisk A/S.
NCT05064735 is a Phase 3 study of Obesity that has completed, run by Novo Nordisk A/S. The registered enrollment target is 407 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (50% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05064735, a Phase 3 study of Obesity, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 407 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will look at participants body weight from the start to the end of the study. It will also look at how much pain participants have in participants knee from the start to the end of the study and how this affects participants daily life. This is to compare the effect on body weight and pain in the knee in people taking semaglutide with people taking "dummy" medicine. Participants will either get semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. During the study, participants will have talks with study staff about how to eat healthy food and how to be more physically active. The study will last for about 1 ½ years. Participants will have 14 clinic visits with the study staff. At the first clinic visit participants will have a blood sample taken. Participants will have an X-ray of participants knee taken at the first visit. If participants have had an X-ray recently, this may not be needed. At 6 of the clinic visits participants cannot take pain medications for 3 days before the visit. Participants cannot take part if participants have had a joint replacement surgery in participants knee. Participants cannot take part if participants have or have had diabetes. Women: Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.
Primary Outcome
Percentage change in body weight from baseline (week 0) to end of treatment (week 68) is presented. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.
Conditions Studied
Interventions
- DRUG semaglutide 2.4 mg
- DRUG semaglutide 2.4 mg (placebo)
Study Locations (20)
California
- Anaheim Clinical Trials, LLC - Anaheim
- Stuart L. Silverman MD - A Medical Corporation - Beverly Hills
- Valley Research - Fresno
- Providence Medical Foundation - Fullerton
- Desert Oasis Hlthcr Med Group - Palm Springs
- Encompass Clinical Research_Spring Valley - Spring Valley
- Diablo Clinical Research, Inc. - Walnut Creek
Florida
- Clinical Research of Hollywood_Hollywood - Hollywood
- Westside Center For Clinical Research - Jacksonville
- Jacksonville Ctr For Clin Res - Jacksonville
- Well Pharma Medical Research Corp - Miami
- Renstar Medical Research - Ocala
- Clinical Trial Res Assoc,Inc - Plantation
Illinois
- Clinical Invest Special_Gurnee - Gurnee
- Evanston Premier Hlthcr Res - Skokie
- Clinical Invest Special_Gurnee - Wauconda
Alabama
- Baptist Health System - Montgomery
Arizona
- Ortho Arizona - Phoenix
Hawaii
- East West Medical Research Institute_Honolulu - Honolulu
Indiana
- MediSphere Medical RC - Evansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 407 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2023-09-08 |
| Phase | Phase 3 |
What the finished NCT05064735 record still lists
NCT05064735 is an interventional study that assigns participants to a tested intervention. The registered 407 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which semaglutide 2.4 mg is the first listed.
NCT05064735 names 20 study sites across 7 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT05064735 about?
NCT05064735 is a clinical study titled "Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis". This study will look at participants body weight from the start to the end of the study. It will also look at how much pain participants have in participants knee from the start to the end of the study and how this affects participants daily life. This is to compare the effect on body weight and pai...
What is the current status of trial NCT05064735?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 407 participants. The study started on 2021-10-01. Estimated completion is 2023-09-08.
What conditions does trial NCT05064735 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT05064735?
The interventions under investigation include: semaglutide 2.4 mg (DRUG), semaglutide 2.4 mg (placebo) (DRUG).
Who is sponsoring clinical trial NCT05064735?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05064735 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05064735's enrollment target sits among peer trials
407 167th of 1053 higher than 887 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06735534 · 407 participants · NA
Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System
- NCT07094516 · 407 participants · Phase 2
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
- NCT04835428 · 408 participants · NA
STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients With Vertebral Compression Fractures
- NCT05836324 · 408 participants · Phase 1
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI